REGENERON PHARMACEUTICALS, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
C07K PEPTIDES 3914
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 30752
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 22728
 
 
 
A01K ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS1862
 
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 7929
 
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 40166
 
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 2772
 
 
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 20105
 
 
 
A61M DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY 12142
 
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 841

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0057,580 ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSIONAug 23, 17Mar 01, 18[A61K, C07K]
2018/0057,583 ANTI-IL-25 ANTIBODIES AND USES THEREOFNov 07, 17Mar 01, 18[A61K, C07K]
2018/0049,413 GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOFNov 06, 17Feb 22, 18[A01K, A61K, C07K]
2018/0036,405 Anti-EGFR Antibodies and Uses ThereofSep 11, 17Feb 08, 18[A61K, C07K]
2018/0036,406 Anti-ErbB3 Antibodies and Uses ThereofOct 25, 17Feb 08, 18[A61K, C07K]
2018/0030,099 Apelin Fusion Proteins and Uses ThereofAug 01, 17Feb 01, 18[A61K, C07K]
2018/0030,480 NOVEL CHO INTEGRATION SITES AND USES THEREOFOct 13, 17Feb 01, 18[C12N]
2018/0020,647 Genetically Modified Non-Human Animals And Methods Of Use ThereofMay 17, 17Jan 25, 18[C12N, A01K]
2018/0015,185 Mice expressing polymorphic low affinity FcgammaR alpha-chainsMay 22, 17Jan 18, 18[A01K, G01N, A61K, C07K]
2018/0016,343 METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONISTJun 20, 17Jan 18, 18[G01N, A61K, C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9913461 Genetically modified mouse whose genome comprises a humanized CD274 geneDec 09, 15Mar 13, 18[C12N, A01K, A61K, G01N, C07K]
9914763 VEGF antagonist formulations suitable for intravitreal administrationApr 11, 16Mar 13, 18[A61M, A61K, C07K]
9901082 Genetically modified non-human animals and methods of use thereofNov 05, 13Feb 27, 18[A01K, A61K, C07K]
9901083 Non-human animals having a humanized signal-regulatory protein geneJun 06, 17Feb 27, 18[C12N, A01K, G01N, A61K, C07K]
9902971 Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generationJun 26, 15Feb 27, 18[C12N, A01K]
9896653 Systems and trays for processing samples by a robotic platformMar 16, 17Feb 20, 18[C12M, B01L, G01N]
9888675 Mice that make heavy chain antibodiesMay 01, 14Feb 13, 18[C12N, A01K, C07K]
9890212 Antibodies to human GDF8Dec 18, 15Feb 13, 18[A61K, C07K]
9884916 High affinity antibodies to human IL-6 receptorApr 22, 16Feb 06, 18[A61K, C07K]
9885058 Production of fertile XY female mice from XY mouse ES cellsApr 12, 17Feb 06, 18[C12N, A01K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0296,657 Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9AbandonedJun 22, 17Oct 19, 17[A61K, C07K]
2017/0226,197 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFICALLY ANTAGONIZING GDF8 AND OR ACTIVIN AAbandonedSep 30, 16Aug 10, 17[C07K]
2017/0073,407 VEGF ANTAGONIST FORMULATIONSAbandonedNov 03, 16Mar 16, 17[C07K]
2017/0008,956 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFICALLY ANTAGONIZING GDF8 AND OR ACTIVIN AAbandonedMar 22, 16Jan 12, 17[C07K]
2016/0316,728 ES Cell-Derived Mice From Diploid Host Embryo InjectionAbandonedJul 11, 16Nov 03, 16[C12N, A01K]
2016/0257,757 METHOD OF TREATING STRESS HYPERGLYCEMIA WITH HUMAN ANTIBODIES TO THE GLUCAGON RECEPTORAbandonedMay 20, 16Sep 08, 16[C07K]
2016/0219,847 COMMON LIGHT CHAIN MOUSEAbandonedFeb 29, 16Aug 04, 16[A01K]
2016/0144,025 METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASESAbandonedNov 17, 15May 26, 16[A61K]
2016/0108,360 GENETIC MODIFICATION OF RATSAbandonedOct 30, 15Apr 21, 16[C12N]
9315843 Methods of producing hybrid antibodiesWithdrawnNov 14, 13Apr 19, 16[C12N, A01K, C12P, C07K]
2016/0102,147 Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) AntibodiesAbandonedDec 09, 15Apr 14, 16[A61M, C07K]
2016/0075,772 Treatment of Fibrodysplasia Ossificans ProgressivaAbandonedSep 10, 15Mar 17, 16[A61K, C07K]
2016/0060,657 METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOMEAbandonedOct 30, 15Mar 03, 16[C12N]
2016/0052,986 HUMANIZED IL-7 RODENTSAbandonedNov 10, 15Feb 25, 16[A01K, C07K]
2016/0046,960 METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATIONS AND METHODS OF USEAbandonedOct 29, 15Feb 18, 16[C12N, A01K]
2016/0032,015 Stabilized Formulations Containing Anti-PCSK9 AntibodiesAbandonedOct 20, 15Feb 04, 16[C07K]
2016/0002,332 Anti-ASIC1 Antibodies and Uses ThereofAbandonedSep 09, 15Jan 07, 16[C07K]
2015/0376,267 HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4AbandonedJun 03, 15Dec 31, 15[C07K]
2015/0366,175 HUMANIZED IL-15 ANIMALSAbandonedSep 01, 15Dec 24, 15[A01K]
2015/0342,163 GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICEAbandonedAug 19, 15Dec 03, 15[A01K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.